Choosing the first biologic in pediatric Crohn's disease: Evidence, uncertainty, and the continuing role of anti-TNF therapy
Best Practice & Research Clinical Gastroenterology · 2026-10 · 102163
DOI: 10.1016/j.bpg.2026.102163 ↗Kurz gefasst
Fachartikel in der Zeitschrift Best Practice & Research Clinical Gastroenterology, 2026-10. Verfasst von Toshihiko Kakiuchi. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The expanding therapeutic landscape of pediatric Crohn’s disease has made selection of the first biologic increasingly complex. This practical review evaluates whether tumor necrosis factor (TNF) inhibition should remain the reference first-biologic strategy, focusing on evidence generated at or near treatment initiation rather than cross-trial efficacy estimates. Infliximab has uniquely direct randomized first-line strategy data and long-term pediatric follow-up, while adalimumab is supported by first-line cohorts and comparative studies showing broadly similar outcomes within the anti-TNF class. Ustekinumab is the strongest non-TNF challenger, with prospective phase 3 pediatric data including a substantial subgroup without previous biologic failure. Vedolizumab has prospective pediatric efficacy data and preliminary mixed-inflammatory-bowel-disease comparative evidence, but Crohn’s disease-specific first-line comparisons remain limited. Published pediatric selective interleukin-23 evidence is still concentrated in refractory disease. Anti-TNF therapy therefore remains the most evidence-secure reference first-biologic class, not because alternative mechanisms have been shown to be inferior, but because its first-line evidence is the most direct and mature. Individual selection should also incorporate disease behavior, perianal disease, growth, need for rapid control, treatment burden, safety context, and family preference.
Zitieren
APA
Kakiuchi, T. (2026). Choosing the first biologic in pediatric Crohn's disease: Evidence, uncertainty, and the continuing role of anti-TNF therapy. Best Practice & Research Clinical Gastroenterology, 102163. https://doi.org/10.1016/j.bpg.2026.102163
Vancouver
Kakiuchi T. Choosing the first biologic in pediatric Crohn's disease: Evidence, uncertainty, and the continuing role of anti-TNF therapy. Best Practice & Research Clinical Gastroenterology. 2026:102163. doi:10.1016/j.bpg.2026.102163
BibTeX
@article{Kakiuchi2026,
author = {Kakiuchi, Toshihiko},
title = {Choosing the first biologic in pediatric Crohn's disease: Evidence, uncertainty, and the continuing role of anti-TNF therapy},
journal = {Best Practice & Research Clinical Gastroenterology},
year = {2026},
pages = {102163},
doi = {10.1016/j.bpg.2026.102163}
}
EUVIMED